

Press release

Zug, 11 August 2009

HBM BioVentures: Agenda for the Shareholders' Meeting

The Board of Directors of HBM BioVentures proposes to its shareholders the cancellation of the shares repurchased under the existing share buy-back programme, and the launch of a new share buy-back programme of up to 20% of the outstanding shares. Disposable liquidity will be used for share buy-backs rather than for new investments in private companies until the discount of the share price compared to the net asset value (NAV) is less than 15%. Mr Robert A. Ingram and Dr Rudolf Lanz stand for re-election to the Board of Directors. Mr Hans Peter Hasler is being proposed as a member of the Board of Directors to replace Dr Karl Preisig.

HBM BioVentures has distributed the invitation for the 8th ordinary shareholders' meeting, to be held on 4 September 2009 in Zug, to its shareholders today. It contains the following agenda items:

1. Annual report, statutory financial statements and consolidated financial statements 2008/2009; reports of the statutory auditors
2. Discharge from liability of the members of the Board of Directors and Management
3. Appropriation of results
4. Elections to the Board of Directors
5. Election of the auditors
6. Reduction in equity capital (cancellation of own shares)
As part of the share buy-back programme adopted in September 2008, the company has acquired a total of 424,952 of its own shares via the second trading line on SIX Swiss Exchange Ltd so far. The Board of Directors proposes these shares for cancellation.
7. Approval of a new share buy-back programme and capital reduction
With the 2009 buy-back programme, the Board of Directors wants to keep open the option of repurchasing own shares up to a maximum of 20% via the second trading line in order to cancel them as part of a capital reduction. These buy-backs shall be effected in the future depending on how business, disposable liquidity and the markets develop.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Should the share price remain heavily undervalued following the repurchase of the aforementioned 20%, a third buy-back programme would be recommended to the shareholders' meeting. As long as share prices are conducive to buy-backs, the company will refrain from the less attractive option of a par value repayment.

HBM BioVentures Ltd will not make any further investments in private companies (except follow-on financings) until the average discount of the share price compared with the average net asset value (NAV) per share is less than 15% for a continuous three-month period. Until then, any disposable liquid funds shall be used to repurchase own shares.

8. Miscellaneous

The detailed invitation to the 8th ordinary shareholders' meeting is available via the following link on the HBM BioVentures Ltd website www.hbmbioventures.com:
<http://www.hbmbioventures.com/en/04-downloads/pressemitteilungen-2009.asp?navanchor=1010031>

For further information, please contact Dr. Joachim Rudolf, CFO HBM BioVentures Ltd, tel.: +41 41 768 11 08, joachim.rudolf@hbmbioventures.com.

Brief profile of HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 35 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on emerging companies that are not yet listed, with two-thirds of assets invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com